Aluminum phosphate poisoning: Successful recovery of multiorgan failure in a pediatric patient

Zachary Henaa,*, Megan E. McCabeb, Michelle M. Perczb, Madhu Sharmaa, Nicole J. Suttona, Giles J. Peeka, Bradley C. Clarka

a Division of Pediatric Cardiology, Department of Pediatrics, The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA
b Division of Pediatric Critical Care Medicine, Department of Pediatrics, The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA
c Division of Pediatric Cardiothoracic Surgery, The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA

ABSTRACT

Aluminum phosphate (AlP) is an insecticide and rodenticide that produces phosphine gas when exposed to moisture. Exposure to AlP has been described as through inhalation and ingestion routes and is typically either accidental or a suicidal attempt. The result is potential multiorgan toxicity involving the heart, kidneys, lungs, and liver, with an overall mortality related to exposure reported from 30% to 77%. The initial symptoms are nonspecific and can include epigastric pain, vomiting, diarrhea, dizziness, and dyspnea. Patients rapidly experience multisystem organ failure, cardiovascular collapse, and, finally, death. We report the case of a 3 year old girl with AlP poisoning who developed cardiogenic shock, ventricular arrhythmias, respiratory failure, liver injury, and significant acute kidney injury (AKI). She was successfully supported with veno-arterial extracorporeal membrane oxygenation (ECMO) for 16 days, treated with lidocaine and magnesium sulfate for ventricular arrhythmias, and received continuous renal replacement therapy (CRRT) and hemodialysis for 24 days for metabolic acidosis secondary to AKI. Despite her severe clinical presentation, she had complete normalization of her end-organ dysfunction with no neurological sequelae. This case demonstrates the high index of suspicion required for AlP poisoning given the potential for rapid progression and severe multiorgan toxicity. The authors recommend prompt referral to a tertiary care center with ECMO and CRRT capability in cases of suspected or documented AlP poisoning.

© 2018 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Aluminum phosphate (AlP) is an insecticide and rodenticide commonly used for agricultural purposes [1,2]. Inhalation or ingestion of aluminum phosphate leads to the production of phosphine gas when exposed to moisture [1,2]. The result is potential multiorgan toxicity involving the heart, kidneys, lungs, and liver [1–3] with an overall mortality related to exposure reported from 30% to 77% [3–6]. Proposed mechanisms of toxicity include inhibition of mitochondrial oxidation with severely decreased mitochondrial membrane potential and inhibition of cytochrome C oxidase, which leads to increased production of reactive oxygen species [7,8]. Patients rapidly experience multisystem organ failure, cardiovascular collapse, and, finally, death.

2. Case report

A previously healthy 3-year-old girl initially presented to an outside emergency room (ER) with a 1 day history of multiple episodes of nonbilious/nonbloody emesis; she was treated for suspected acute gastroenteritis and discharged home after receiving IV fluids and tolerating oral liquids. A few hours later, her 17-year-old brother presented to the same ER with symptoms of abdominal pain, nausea, and vomiting. Further history revealed that their father had used aluminum phosphate pellets around the

* Corresponding author. Division of Pediatric Cardiology, Department of Pediatrics, Children’s Hospital at Montefiore, Albert Einstein College of Medicine, 3415, Bainbridge Avenue, Bronx, NY, 10467, USA.
E-mail address: zhena@montefiore.org (Z. Hena).
Peer review under responsibility of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia.

https://doi.org/10.1016/j.ijpam.2018.09.001
2352-6467/© 2018 Publishing services provided by Elsevier B.V. on behalf of King Faisal Specialist Hospital & Research Centre (General Organization), Saudi Arabia. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
apartment and in the children’s beds to eradicate *Cimex lectularius* (bed bugs). The brother was admitted to receive IV fluids, observed, and discharged without any clinical sequelae of toxicity. The family was from Bangladesh where the pellets can be legally obtained; the pellets were purchased from the Bronx, through their local community. The pellets contained 55% aluminum phosphate. The 3-year-old girl was called back to the ER 11 hours after initial presentation, and on arrival, she was found to be tachycardic (152 beats/min) and hypotensive (66/46 mmHg) and appeared weak and tired. A venous blood gas analysis was performed, and the results demonstrated an anion gap acidosis. Additionally, electrocardiogram (ECG) showed nonspecific ST changes with minimal depression, which was more evident in the inferior and lateral leads (Fig. 1). She was given boluses of normal saline but did not show improvement in blood pressure or heart rate, and she was subsequently started on a dopamine infusion. Clinical examination and rapid deterioration was concerning for cardiogenic shock; therefore, she was transferred to our institution for possible extracorporeal membrane oxygenation (ECMO) support.

Upon arrival, she was found to be tachypneic, tachycardic, and hypotensive with a gallop rhythm on examination and evidence of poor clinical cardiac output. Baseline laboratory values are listed in Table 1. Echocardiogram demonstrated severely depressed left ventricular systolic function with an ejection fraction (EF) of 26% and moderately depressed right ventricular systolic function.

Table 1. Baseline laboratory values.

| Parameter                        | Value     | Reference   |
|----------------------------------|-----------|-------------|
| Sodium, mEq/L                    | 139       | 135–145     |
| Potassium, mEq/L                 | 4.4       | 3.5–5.0     |
| Chloride, mEq/L                  | 105       | 98–108      |
| Carbon dioxide, mEq/L            | 10        | 22–29       |
| Blood urea nitrogen, mg/dL       | 25        | 4–21        |
| Creatinine, mg/dL                | 0.4       | 0.40–0.70   |
| Calcium, mg/dl                   | 9.1       | 8.5–10.5    |
| Anion gap, mEq/L                 | 24        | 7–16        |
| Alanine Aminotransferase, U/L     | 16        | <= 25       |
| Aspartate Aminotransferase, U/L   | 31        | 11–42       |
| White Blood Cell Count, k/ul     | 9.0       | 6.0–17.5    |
| Hemoglobin, g/dl                 | 10.5      | 11.7–13.8   |
| Hematocrit, %                    | 33.0      | 34.0–40.0   |
| Platelet Count, k/ul             | 246       | 150–400     |
| Arterial Blood Gas               |           |             |
| pH                               | 7.335     | 7.350–7.450 |
| pCO₂, mmHg                       | 21.5      | 35.0–45.0   |
| pO₂, mmHg                        | 154.0     | 80–100      |
| HCO₃, mmol/L                     | 11.2      | 22.0–28.0   |
| Lactic Acid, mmol/L              | 3.1       | 0.0–2.2     |

During the subsequent 6 hours, she developed decompensated cardiogenic shock with worsening acidosis and an increasing lactate level. She required intubation, escalation of dopamine, and addition of an epinephrine infusion. Immediately following intubation, she developed wide complex tachycardia followed by bradycardia and pulseless electrical activity requiring extracorporeal cardiopulmonary resuscitation (ECPR).

She was supported with veno-arterial (VA) ECMO for 16 days. A balloon atrial septoplasty was performed for pulmonary edema while on ECMO on hospital day (HD) 4. She had severely depressed biventricular function and regained pulsatility on HD 15. The next day, she was decannulated with residually depressed left ventricular systolic function (EF 35%) and normal right ventricular systolic function. With regard to her cardiac rhythm, she required aggressive treatment of ventricular tachycardia and torsades de pointes (Fig. 2), with magnesium sulfate (MgSO₄) and lidocaine within the first 2 days of admission. The initial dose of MgSO₄ was 25 mg/kg followed by a dose of 50 mg/kg. She was given a 1 mg/kg/dose bolus of lidocaine and then started on a continuous infusion of 20 mcg/kg/min that was titrated to 40 mcg/kg/min. Lidocaine was weaned secondary to a change observed in her neurological examination with concerns for seizure activity; however, her EEG showed no evidence of epileptiform activity. Antiarrhythmics were successfully discontinued in the patient on HD 3, and she did not show recurrence of tachycardia. N-acetylcysteine (NAC) was administered as treatment for cardiotoxicity secondary to oxidative stress during the first 3 days of her hospitalization in three doses: a 150 mg/kg/dose as a loading dose, followed by a 50 mg/kg/dose, and finally 100 mg/kg/dose.

Continuous renal replacement therapy (CRRT) was started within 13 hours of admission for severe metabolic acidosis. She was oliguric for the first 7 days of hospitalization followed by 11 days of anuria. A MAG3 scan during hospitalization was consistent with acute tubular necrosis. She continued CRRT for a total of 23 days followed by 1 day of hemodialysis; she was subsequently started on enteral diuretics. Four weeks after admission, her creatinine level normalized. Her aspartate aminotransferase (AST) level peaked on HD 1 at 6874 U/L, and her liver function did not normalize until 16 days later. Fig. 3 shows the trends and normalization of Troponin-T, creatinine, and AST.

Throughout hospitalization, she suffered no significant neurological sequelae and had a normal result in neurological examination on discharge. On HD 36, she was discharged to an acute care rehabilitation center on furosemide and carvedilol for heart failure. Six weeks later, during an outpatient cardiology follow-up visit, she returned to school with no focal neurological deficits. She had normal biventricular systolic function on echocardiogram, normal
electrolyte levels, and renal function on basic metabolic panel, and her only medication was carvedilol, which was continued for cardiac remodeling.

3. Discussion

AlP poisoning can have a varied presentation and clinical course. The initial symptoms can be nonspecific and include epigastric pain, vomiting, diarrhea, dizziness, and dyspnea [1,4]. Emesis has been reported to have a garlic odor, which may increase suspicion for AlP poisoning [5]. Exposure has been described as through inhalation and ingestion routes and is typically either accidental or a suicidal ingestion [3,6–8]. In our case, the mechanism of exposure was accidental inhalation of phosphine gas from an insecticide related to placement of pellets for attempted bed bug eradication. Cardiovascular complications including dysrhythmias (bradyarrhythmias and ventricular arrhythmias such as ventricular tachycardia (VT)) and systolic heart failure ranging from decreased cardiac function to complete cardiovascular collapse are common in AlP poisoning [8–11]. The initial ECG for our patient showed diffuse ST depression similar to acute presentations of myocarditis. She developed VT and torsades de pointes 2 days after ECMO cannulation (Fig. 2); it was controlled with the combination of lidocaine and MgSO4, and after 2.5 days, lidocaine was successfully weaned without further recurrence of ventricular arrhythmias. Lidocaine, MgSO4, and amiodarone have been used to convert VT to sinus rhythm in patients with AlP toxicity [9,12], but there is also description of treatment failure with both of these medications as well as electrical cardioversion [13]. Interestingly, ours is the first case described in a pediatric patient with successful termination of VT and torsades de pointes with lidocaine and MgSO4 while supported with ECMO.

ECMO has been well described for reversible cardiogenic shock in patients with AlP poisoning [8,14–17]. Our patient required ECMO for 16 days, which is slightly longer than the typical course of cardiogenic shock (7–14 days) in patients with AlP poisoning [8,11]. Prompt referral to an ECMO center and initiation of support for patients with severe metabolic acidosis, refractory shock, and severe left ventricular dysfunction have been associated with improved survival [14,15]. The EF of our patient was 26% at presentation, improved to 35% at the time of decannulation from ECMO and further improved to 40% before discharge (31 days after initiation of ECMO). At follow-up 3 months later, she had normal biventricular function with a left ventricular EF of 59%; her right ventricular systolic function had normalized at the time of decannulation. Her Troponin-T on ECMO day 2 was elevated to 4.06 ng/mL, peaked on ECMO day 10 at 4.37 ng/mL, decreased to 1.72 ng/mL, and continued to trend down thereafter. She was maintained on carvedilol for chronic heart failure and cardiac remodeling.

ECMO has been well described for reversible cardiogenic shock in patients with AlP poisoning [8,14–17]. Our patient required ECMO for 16 days, which is slightly longer than the typical course of cardiogenic shock (7–14 days) in patients with AlP poisoning [8,11]. Prompt referral to an ECMO center and initiation of support for patients with severe metabolic acidosis, refractory shock, and severe left ventricular dysfunction have been associated with improved survival [14,15]. The EF of our patient was 26% at presentation, improved to 35% at the time of decannulation from ECMO and further improved to 40% before discharge (31 days after initiation of ECMO). At follow-up 3 months later, she had normal biventricular function with a left ventricular EF of 59%; her right ventricular systolic function had normalized at the time of decannulation. Her Troponin-T on ECMO day 2 was elevated to 4.06 ng/mL, peaked on ECMO day 10 at 4.37 ng/mL, decreased to 1.72 ng/mL, and continued to trend down thereafter. She was maintained on carvedilol for chronic heart failure and cardiac remodeling. NAC, which was administered to our patient, has been described as treatment for cardiotoxicity secondary to oxidative stress in AlP poisoning, and its use has been associated with a decreased hospital length of stay [18].

Interruption of hemodialysis, CRRT, and peritoneal dialysis have all been described as treatment for acute renal failure and metabolic acidosis in AlP poisoning [19–21]. Bayazit et al. reported a case of a 12-year-old girl who had normalization of renal function in 10 days [19], but they did not report the length of hemodialysis requirement. Nasa et al. report CRRT support for 3 days in two adults [20] with AlP poisoning but did not describe when their renal function recovered. An additional report described the use of peritoneal dialysis for 3 days in one patient and for 4 days in another patient, but the authors did not comment on renal function [21]. Our patient was supported with CRRT for 23 days, with one additional day of intermittent hemodialysis. Her MAG3 scan during hospitalization was consistent with acute tubular necrosis, which has been reported in another case [22], and her creatinine level normalized within 4 weeks. Two months post discharge, she had normal renal function and urine output and had been able to maintain normal electrolytes and acid–base balance.

We presented a rare case of pediatric AlP poisoning that was associated with cardiogenic shock, ventricular arrhythmias, liver...
involvement, and significant acute kidney injury. Despite her severe clinical presentation, she had complete normalization of her end-organ dysfunction, although long-term sequelae will likely not be known for some time. A high index of suspicion for AIP poisoning is necessary given the potential for rapid progression of multisystem organ failure, cardiovascular collapse, and death. Factors that have been associated with decreased survival include ECG changes (ST segment depression and sinus tachycardia) and metabolic acidosis on arterial blood gas analysis at presentation [1]. Given the multisystem organ failure and high risk of morbidity and mortality, we would recommend prompt referral to a tertiary care center that can provide ECMO and CRRT or hemodialysis in cases of suspected or documented AIP poisoning. Furthermore, our case highlights the potential for slow clinical improvement of end-organ injury, especially with regard to cardiac function. While she has had full resolution of symptoms and end-organ damage, close follow-up is necessary given the long-term potential for morbidity and lack of long-term follow-up data for cases of AIP poisoning.

Financial disclosure

The authors declare that they have no financial relationships relevant to this article to disclose.

Funding source

No external funding was received for this study.

Conflict of interest

The authors declare that they have no potential conflicts of interest to disclose.

Abbreviations

AIP  Aluminum phosphide
AST  aspartate aminotransferase
CRRT  continuous renal replacement therapy
ECG  electrocardiogram
ECMO  extracorporeal membrane oxygenation
ECPR  extracorporeal cardiopulmonary resuscitation
EF  ejection fraction
ER  emergency room
HD  hospital day
NAC  N-acetylcysteine
MgSO4  magnesium sulfate
VA  veno-arterial
VT  ventricular tachycardia

References

[1] Shadnia S, Sasanian G, Allami P, Hosseini A, Ranjarb A, Amini-Shirazi N, et al.

A retrospective 7-years study of aluminum phosphate poisoning in Tehran: opportunities for prevention. Hum Exp Toxicol 2009 Apr;28(4):209-13.

[2] Proudfoot AT. Aluminum and zinc phosphate poisoning. Clin Toxicol 2009 Feb;47(2):89–100.

[3] Bumbrah GS, Krishan K, Kanchan T, Sharma M, Sodhi GS. Phosphate poisoning: a review of literature. Forensic Sci Int 2012 Jan 10;214(1–3):1–6.

[4] Sharma A, Dhangat VG, Kaushik JS, Mittal K. Aluminum phosphate (celphos) poisoning in children: a 5-year experience in a tertiary care hospital from northern India. Indian J Crit Care Med: peer-reviewed, official publication of Indian Society of Critical Care Medicine 2014 Jan;18(1):33.

[5] Møller FE, Kristensen AK, Bredahl C. Survival after oral poisoning with insecticide against moles containing aluminum phosphate. Ugeskr Laeger 2013 Jun;175(24):1704-5.

[6] Chugh SN, Ram S, Aroba B, Malhotra KC. Incidence & outcome of aluminum phosphate poisoning in a hospital study. Indian J Med Res 1991 Jun;94:232-5.

[7] Bogle RG, Theron P, Brooks P, Dargan PI, Redhead J. Aluminum phosphate poisoning. Emerg Med J 2006 Jan 1;23(1):e03.

[8] Elbibassi W, Chowdhury MA, Fachartz AA. Severe reversible myocardial injury associated with aluminum phosphate toxicity: a case report and review of literature. Journal of the saudi heart association 2014 Oct 1;26(4):216-21.

[9] Siwach SB, Singh H, Katyal VK, Bhardwaj G. Cardiac arrhythmias in aluminum phosphate poisoning studied by on continuous holter and cardiorespiratory monitoring. J Assoc Phys India 1998 Jul;46(7):598–601.

[10] Soltaninejad K, Beyranvand MR, Momennazadeh SA, Shadnia S. Electrocardiographic findings and cardiac manifestations in acute aluminum phosphate poisoning. Journal of forensic and legal medicine 2012 Jul 1;19(5):291-2.

[11] Akkaoju M, Achoir S, Abidi K, Himdi B, Madani A, Zeggwagh AA, Abouqal R. Reversible myocardial injury associated with aluminum phosphate poisoning. Clin Toxicol 2007 Jan 1;45(6):278-31.

[12] Chugh SN, Malhotra S, Kumar P, Malhotra KC. Reversion of ventricular and supraventricular tachycardia by magnesium sulphate therapy in aluminum phosphate poisoning. Report of two cases. J Assoc Phys India 1991 Aug;39(8):642–3.

[13] Jadhav AP, Nusair MB, Ingole A, Alpert MA. Unresponsive ventricular tachycardia associated with aluminum phosphate poisoning. AJEM (Am J Emerg Med) 2012 May 1;30(4):633-e3.

[14] Mohan B, Gupta V, Ralhan S, Gupta D, Puri S, Wadner GS, et al. Role of extracorporeal membrane oxygenation in aluminum phosphate poisoning—induced reversible myocardial dysfunction: a novel therapeutic modality. J Emerg Med 2015 Nov 1;49(5):651-6.

[15] Mohan B, Singh B, Gupta V, Ralhan S, Gupta D, Puri S, et al. Outcome of patients supported by extracorporeal membrane oxygenation for aluminum phosphate poisoning: an observational study. Indian Heart J 2016 May 1;68(3):295–301.

[16] Merin G, Fink D, Fink DL, Shahroor S, Schlesinger Y, Amir G, et al. Salvage ECMO deployment for fatal aluminum phosphate poisoning. AJEM (Am J Emerg Med) 2015 Nov 1;33(11):1718-e1.

[17] Lehoux J, Henia Z, McCabe M, Peer G. Aluminum phosphate poisoning resulting in cardiac arrest, successful treatment with Extracorporeal Cardiopulmonary resuscitation (ECPR): a case report. Perfusion October 2018;33(7):0267659118777196.

[18] Tehrani H, Halvaei Z, Shadnia S, Soltaninejad K, Abdollahi M. Protective effects of N-acetylcysteine on aluminum phosphate-induced oxidative stress in acute human poisoning. Clin Toxicol 2013 Jan 1;51(1):23–8.

[19] Bayazit AK, Noyan A, Aataran A. A child with hepatic and renal failure caused by aluminum phosphate. Nephron 2000;86(4):317-e.

[20] Nasa P, Gupta A, Mangal K, Nagnani SK, Raina S, Yadav R. Use of continuous renal replacement therapy in acute aluminum phosphate poisoning: a novel therapy. Ren Fail 2013 Sep 1;35(8):1170-2.

[21] Bashardoust B, Farzaneh E, Habibzadeh A, Sadeghi MS. Successful treatment of severe metabolic acidosis due to acute aluminum phosphate poisoning with peritoneal dialysis: a report of 2 cases. Iranian journal of kidney diseases 2017 Mar 1;11(2):165.

[22] Gupta MS, Mehta L, Chugh SN, Malhotra KC. Aluminum phosphate poisoning, Two cases with rare presentation. J Assoc Phys India 1990 Jul;33(7):509.

[23] Yan H, Chen H, Li Z, Shen M, Zhuo X, Wu H, et al. Phosphine analysis in postmortem specimens following inhalation of phosphine: fatal aluminum phosphate poisoning in children. J Anal Toxicol 2018 Jan 25;42(5):330-6.